|Description||AVL-292, also known as CC-292, is an orally bioavailable, selective inhibitor of Bruton’s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, AVL-292 targets and covalently binds to BTK, thereby preventing its activity.|
|Appearance||white solid powder|
|Synonyms||CC-292; CC292; CC 292; AVL292; AVL 292.|
|Current Developer||Avila Therapeutics, Inc.|
Btk inhibitor 1 R enantiomer
Btk inhibitor 1 R enantiomer is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.
CGI1746 is a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation. CGI1746 has exqui...
AVL-292, also known as CC-292, is an orally bioavailable, selective inhibitor of Bruton’s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplas...
GDC-0834 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis. In vitro metabol...
Potent BTK inhibitor (IC50 = 0.3 nM). Blocks B cell antigen receptor (BCR)-mediated gene expression in CD20+ B cells.
ONO-4059 (hydrochloride) is the hydrochloride salt form of Tirabrutinib. ONO-4059 is a highly selective, orally bioavailable BTK inhibitor (IC50= 2.2 nM) and de...
Btk inhibitor 1 R enantiomer hydrochlori
Btk inhibitor 1R enantiomer Hcl is a pyrazolo[3,4-d]pyrimidine derivative as a <strong>Btk </strong>kinase inhibitor.
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It binds to BTK to suppress both B-cell activation and B-cell-mediated signaling.
Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.ACP-196 inhibits...
ONO-4059, a BTK inhibitor, has been found to have potential effect against sorts of malignancies by influencing the B-cell development. It is currently under Ph...
ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.
PCI-32765 Racemate is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK), modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, ...
GDC-0834 is a small molecule inhibitor of Btk potentially useful in the treatment of RA and lymphoid malignancies. Administration of GDC-0834 (30 -- 100 mg/kg)...
Olmutinib, also called as HM61713 and BI-1482694, is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inh...
AVL-292 benzenesulfonate is a covalent, highly selective, orally active small molecule inhibitor of Btk with IC50 value of 0.5 nM; >1400-fold selectivity ove...
Evobrutinib is a highly selective inhibitor of Bruton's tyrosin kinase (Btk) inhibitor.
RN983 is a selective BTK enzyme inhibitor. It inhibits IgG production in B-cells with an IC50 value of 2.5 ± 0.7 nM and PGD2 production from mast cells with an ...
BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achieving higher ...
QL47 is a potent and selective BTK inhibitor, which covalently modifies Cys481. QL47 inhibits BTK kinase activity with an IC50 of 7 nM, inhibits autophosphoryla...
RN486 is a reversible Bruton's tyrosine kinase (Btk) inhibitor with IC50 value of 4.0 nM.